Hyperadrenergic POTS is a subtype of postural orthostatic tachycardia syndrome defined by excessive norepinephrine (adrenaline-family hormone) release when you stand up, typically with standing plasma norepinephrine levels above 600 pg/mL. Where all forms of POTS share the hallmark heart rate jump of 30 or more beats per minute upon standing, the hyperadrenergic form adds a distinctive twist: blood pressure often rises rather than drops, and the surge of sympathetic nervous system activity produces symptoms that go well beyond a racing heart. Understanding this subtype matters because it responds to different treatments than other forms of POTS, and it is frequently tangled up with conditions like mast cell activation syndrome that complicate the picture further.
How Hyperadrenergic POTS Differs From Other Subtypes
POTS is not a single disease but a collection of syndromes that share one diagnostic criterion: a sustained heart rate increase of 30 or more beats per minute within five to thirty minutes of standing, without a large drop in blood pressure.1PubMed Central. The Postural Tachycardia Syndrome (POTS): pathophysiology, diagnosis & management Within that umbrella, clinicians recognize several phenotypes. The neuropathic form involves damage to the small nerve fibers that constrict blood vessels in the legs, letting blood pool downward. The hyperadrenergic form, by contrast, is characterized by an exaggerated sympathetic nervous system response. Researchers generally define it as an upright norepinephrine level above 600 pg/mL or a level more than three times the supine value.2Clinical Autonomic Research. Hyperadrenergic and neuropathic features based on clinical autonomic testing in individuals with POTS: an observational cross-sectional study Some clinicians also use a systolic blood pressure rise of 10 mmHg or more during a head-up tilt test as a marker.3Cardiol J. Clinical presentation and management of patients with hyperadrenergic postural orthostatic tachycardia syndrome. A single center experience.
These aren’t always cleanly separated categories. A recent cross-sectional study found that hyperadrenergic and neuropathic features can overlap in the same patient, making the subtype labels more like descriptions of dominant patterns than rigid boxes.2Clinical Autonomic Research. Hyperadrenergic and neuropathic features based on clinical autonomic testing in individuals with POTS: an observational cross-sectional study Still, the distinction has practical value because the hemodynamic profile differs. In a head-up tilt comparison, hyperadrenergic patients had higher resting heart rates, lower vagal (parasympathetic) tone, and tolerated prolonged tilting substantially longer than the non-hyperadrenergic group, who developed syncope or intolerable symptoms much earlier.4Clinical Neurophysiology. Hemodynamic profile and heart rate variability in hyperadrenergic versus non-hyperadrenergic postural orthostatic tachycardia syndrome In the non-hyperadrenergic patients, diastolic blood pressure tended to fall during the first minutes of standing, while hyperadrenergic patients maintained or increased their blood pressure. This blood pressure behavior is one of the practical clues that helps clinicians tell the two apart at the bedside.
Symptoms Beyond the Racing Heart
Every POTS patient knows the feeling of standing up and having their heart hammer. In hyperadrenergic POTS, that cardiac acceleration comes packaged with a broader set of symptoms driven by the norepinephrine flood. Tremor, especially in the hands, is common. Many people experience a pounding or forceful heartbeat rather than just a fast one. Anxiety-like symptoms such as chest tightness, a sense of dread, and difficulty breathing can appear suddenly on standing. Some patients flush visibly, particularly in the face and upper chest. Headaches and a heavy “pressure” feeling in the head can accompany the blood pressure spike.
One of the most debilitating symptoms across all POTS subtypes is cognitive difficulty, commonly called brain fog. Patients report trouble concentrating, slow processing, and difficulty finding words. This cognitive burden adds a layer of disability that heart rate numbers alone don’t capture.5PubMed Central. What is brain fog? An evaluation of the symptom in postural tachycardia syndrome In long-term surveys, the symptom picture extends to gastrointestinal complaints, fatigue severe enough to be functionally disabling, and limitations in energy and general health that persist for years.6PubMed Central. Long-Term POTS Outcomes Survey: Diagnosis, Therapy, and Clinical Outcomes
A recurring problem for people with hyperadrenergic POTS is being told they “just have anxiety.” The overlap is superficial but convincing to a clinician unfamiliar with the condition: racing heart, shortness of breath, tremor, a sense of panic. Case reports have documented patients spending years diagnosed with an anxiety disorder before the autonomic source of their symptoms was identified.7PubMed Central. Postural Orthostatic Tachycardia Syndrome Misdiagnosed as Anxiety: A Case Report with a Review of Therapy and Pathophysiology The distinction matters because treating hyperadrenergic POTS as anxiety, particularly with medications that raise norepinephrine, can worsen symptoms rather than relieve them.
What Drives the Norepinephrine Surge
The causes of hyperadrenergic POTS aren’t fully mapped, but several mechanisms have been identified. They can operate alone or in combination.
The clearest genetic link comes from a rare mutation in the norepinephrine transporter gene (SLC6A2). This transporter is the protein responsible for sweeping norepinephrine back into nerve terminals after it has been released. In one well-studied family, a single amino acid change (alanine to proline at position 457) wiped out more than 98 percent of the transporter’s function.8PubMed. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency The result is that norepinephrine lingers in the synapse far longer than normal, amplifying every sympathetic signal. Laboratory work showed the mutant transporter also has a “dominant-negative” effect, meaning it drags down the function of the normal copy inherited from the other parent, so even carrying one bad copy causes significant impairment.9PubMed Central. A mutation in the human norepinephrine transporter gene (SLC6A2) associated with orthostatic intolerance disrupts surface expression of mutant and wild-type transporters This mutation is rare, but it offers a clean window into how impaired norepinephrine clearance can create the hyperadrenergic state.
Beyond this single-gene story, autoimmune processes appear to play a broader role. A study found that nearly 90 percent of POTS patients tested had elevated autoantibodies against the adrenergic alpha-1 receptor, and over half had elevated antibodies against a muscarinic acetylcholine receptor. Many of these patients reported viral-like symptoms before their POTS began, fitting the pattern of a post-infectious autoimmune trigger.10PubMed Central. Postural Orthostatic Tachycardia Syndrome Is Associated With Elevated G-Protein Coupled Receptor Autoantibodies If antibodies are stimulating adrenergic receptors or interfering with their regulation, that could push the sympathetic nervous system into overdrive without any structural nerve damage.
A newer line of research focuses not just on how much norepinephrine is circulating, but on how strongly blood vessels respond to it. One study found that hyperadrenergic POTS patients had a similar rate of sympathetic nerve firing compared to non-hyperadrenergic patients, but their blood vessels translated each nerve burst into a much larger blood pressure response. The researchers called this “augmented neurovascular transduction,” suggesting that in some patients, the problem isn’t producing too much norepinephrine per se, but overreacting to normal amounts of it.11PubMed Central. Hyperadrenergic postural tachycardia syndrome associated with augmented neurovascular transduction
The Mast Cell Connection
One of the more striking findings in hyperadrenergic POTS research is how often mast cell activation syndrome (MCAS) appears alongside it. Mast cells are immune cells that release histamine and other inflammatory chemicals. When they activate inappropriately, they can trigger flushing, abdominal pain, diarrhea, and surges in heart rate and blood pressure, symptoms that mimic or amplify a hyperadrenergic POTS episode.
Researchers have identified a subset of POTS patients with both flushing episodes and abnormal urinary markers of mast cell degranulation. These patients show a characteristic hyperadrenergic response to standing, with blood pressure increases and exaggerated cardiovascular reflexes that distinguish them from other POTS patients.12Hypertension. Hyperadrenergic postural tachycardia syndrome in mast cell activation disorders The overlap between hyperadrenergic POTS and MCAS has also drawn attention in the context of long COVID, where all three conditions can appear together.13PubMed Central. Complete remission with histamine blocker in a patient with intractable hyperadrenergic postural orthostatic tachycardia syndrome secondary to long coronavirus disease syndrome
The practical implication is that if you have hyperadrenergic POTS and also experience episodes of flushing, hives, gastrointestinal cramping, or symptoms that seem to flare after certain foods or environmental triggers, it is worth investigating MCAS as a contributing factor. In at least one reported case of long-COVID-related hyperadrenergic POTS with MCAS features, treatment with a histamine blocker led to complete remission of symptoms.13PubMed Central. Complete remission with histamine blocker in a patient with intractable hyperadrenergic postural orthostatic tachycardia syndrome secondary to long coronavirus disease syndrome That is a single case, not a guarantee, but it underscores why identifying mast cell involvement changes the treatment approach.
The Ehlers-Danlos Overlap
Hypermobile Ehlers-Danlos syndrome (hEDS) and related hypermobility spectrum disorders show a remarkably high co-occurrence with POTS. In one study of women with these connective tissue conditions, about 58 percent reported a physician diagnosis of POTS, and a quarter carried all three diagnoses of hEDS, POTS, and MCAS simultaneously.14Autonomic Neuroscience. Autonomic symptom burden, comorbidities and quality of life in women with Hypermobility Spectrum Disorders and hypermobile Ehlers-Danlos syndrome A separate pilot study found POTS was significantly more common in the hEDS group compared to those with other Ehlers-Danlos subtypes.15Journal of Invasive Cardiology. The prevalence of cardiac symptoms in Ehlers-Danlos syndrome and hypermobility spectrum disorder: a pilot study
The connection isn’t fully understood. One theory is that overly stretchy connective tissue in veins allows excessive blood pooling, triggering a compensatory sympathetic surge. Another is that the same genetic and immune factors that produce connective tissue laxity also affect autonomic regulation. Whatever the mechanism, if you are being evaluated for POTS and also have joint hypermobility, chronic pain, or easy bruising, raising the possibility of a connective tissue disorder with your doctor can open up relevant testing and treatment adjustments.
Diagnosing the Hyperadrenergic Subtype
The baseline POTS diagnosis typically comes from a head-up tilt table test or an active standing test showing the characteristic heart rate rise without a significant blood pressure drop. Distinguishing the hyperadrenergic subtype requires a step further. The most direct approach is measuring plasma norepinephrine levels while supine and again after ten minutes of standing. An upright norepinephrine above 600 pg/mL, or a rise to more than three times the supine value, points toward hyperadrenergic physiology.16The FASEB Journal. Hyperadrenergic activity and the Postural Tachycardia Syndrome (PoTS) Some centers also look at the blood pressure response during the tilt: a systolic rise of 10 mmHg or more during upright posture, combined with tachycardia, supports the hyperadrenergic label.3Cardiol J. Clinical presentation and management of patients with hyperadrenergic postural orthostatic tachycardia syndrome. A single center experience.
More specialized centers use the Valsalva maneuver, a forced exhale against a closed airway, as a bedside autonomic test. In hyperadrenergic POTS patients, the blood pressure behavior during certain phases of the Valsalva can reflect exaggerated sympathetic tone. A recent study found that the blood pressure recovery pattern during the Valsalva correlated well with direct recordings of sympathetic nerve activity, making it a useful clinical biomarker for identifying the hyperadrenergic phenotype without the need for invasive nerve recordings.17PubMed Central. Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine
Ruling out other causes of catecholamine excess is also part of the workup. A pheochromocytoma, a rare adrenal gland tumor, can produce very similar symptoms, as can other conditions that dump catecholamines into the bloodstream.18Cor et Vasa. Current look on postural tachycardia syndrome There are case reports of endocrine tumors initially misdiagnosed as POTS because the symptom overlap is so convincing.19PubMed Central. MEN2B Masquerading as Postural Orthostatic Tachycardia Syndrome Screening for pheochromocytoma, usually through urine or blood tests for catecholamine metabolites, is a standard part of the evaluation.
Treatment Strategies
Treatment for hyperadrenergic POTS targets both the general POTS physiology, specifically low blood volume and deconditioning, and the specific problem of sympathetic overdrive. Most clinicians start with non-drug measures before adding medications.
Volume Expansion and Exercise
Increasing salt and fluid intake is a first-line recommendation across POTS subtypes. A controlled study found that a high-sodium diet in POTS patients produced a smaller heart rate jump on standing compared to a low-sodium diet, with the benefit driven almost entirely by expanding plasma volume.20Journal of the American College of Cardiology. Effect of High Dietary Sodium Intake in Patients with Postural Tachycardia Syndrome Standing norepinephrine levels also dropped on the high-salt diet, which is particularly relevant for the hyperadrenergic subtype.
Exercise is the other foundational intervention, but the approach matters. Cardiovascular deconditioning, including shrinkage of the heart and reduced blood volume, contributes significantly to POTS symptoms. Exercise training can reverse this, but starting with upright exercise often backfires because standing triggers the very symptoms you are trying to treat. The recommended strategy is to begin with horizontal or semi-recumbent exercises like rowing, swimming, or recumbent cycling, and gradually introduce upright activity as tolerance improves.21PubMed Central. Exercise and non-pharmacological treatment of POTS
Medications That Quiet the Sympathetic System
When non-drug measures are not enough, medications for hyperadrenergic POTS typically aim to dampen sympathetic outflow. Clonidine, a centrally-acting drug that reduces sympathetic nerve activity from the brain, has been studied specifically in hyperadrenergic POTS. In one trial, clonidine reduced markers of sympathetic nervous system firing. Among participants who stayed on clonidine for more than six months, the large majority reported fewer symptoms than at baseline.22Heart Rhythm. Using Clonidine for neuromodulation in patients with postural orthostatic tachycardia syndrome Guanfacine, a related centrally-acting agent, has also been investigated as a biomarker-guided treatment option for the hyperadrenergic phenotype.17PubMed Central. Hyperadrenergic Postural Tachycardia Syndrome: Clinical Biomarkers and Response to Guanfacine Both drugs can cause drowsiness, dry mouth, and low blood pressure, so they require careful dose adjustment.
One medication to be cautious about is atomoxetine, a norepinephrine reuptake inhibitor sometimes prescribed for POTS in an attempt to increase blood vessel constriction. Because it blocks the same norepinephrine transporter that is already underperforming in many hyperadrenergic patients, it can raise standing heart rate and worsen self-reported symptoms.23US Cardiology Review. Narrative Review of Postural Orthostatic Tachycardia Syndrome: Associated Conditions and Management Strategies This is a good example of why subtyping matters: a treatment that helps one POTS phenotype can make another one worse.
For patients whose hyperadrenergic POTS is driven by mast cell activation, adding antihistamines or mast cell stabilizers can address the upstream trigger rather than just the downstream heart rate response. Beta-blockers like propranolol are widely used across POTS subtypes to blunt the heart rate rise, though in the hyperadrenergic form they treat the symptom (tachycardia) without addressing the underlying sympathetic overdrive. A combination approach, pairing a centrally-acting sympatholytic with a beta-blocker and a mast cell treatment if applicable, is common in clinical practice.
Pregnancy and Hyperadrenergic POTS
Because POTS disproportionately affects women of childbearing age, pregnancy is a frequent concern. The good news is that many women with POTS have uneventful pregnancies and deliveries. The challenging news is that pregnancy itself introduces physiological changes that can interact with POTS in unpredictable ways. Hyperemesis gravidarum (severe nausea and vomiting) can worsen POTS through volume depletion. Pregnancy-related anemia reduces oxygen delivery. And some POTS medications, including clonidine and certain beta-blockers, require reassessment for safety during pregnancy.24PubMed Central. POTS and Pregnancy: A Review of Literature and Recommendations for Evaluation and Treatment
Interestingly, some women report that their POTS symptoms improve during the second and third trimesters, likely because of the natural blood volume expansion that occurs during pregnancy. Others find symptoms worsen, particularly in the first trimester when nausea and dehydration are common. The postpartum period is its own risk zone: the sudden drop in blood volume after delivery can trigger a severe POTS flare. Planning ahead with an obstetrician who understands autonomic disorders, ideally before conception, helps ensure that medication swaps and monitoring protocols are in place rather than scrambled together reactively.
When Hyperadrenergic POTS Is Not POTS at All
The hyperadrenergic symptom cluster, including pounding heart, tremor, flushing, and blood pressure spikes on standing, isn’t exclusive to POTS. One important mimic is pheochromocytoma or paraganglioma, tumors that secrete catecholamines directly into the bloodstream. The presentation can look strikingly similar, with episodes of tachycardia and hypertension triggered by positional changes or stress. A case report documented a patient with MEN2B, a hereditary endocrine tumor syndrome, who was initially managed as POTS before the underlying tumor was discovered.19PubMed Central. MEN2B Masquerading as Postural Orthostatic Tachycardia Syndrome Inappropriate sinus tachycardia, vasovagal syncope, and other supraventricular arrhythmias can also overlap clinically.18Cor et Vasa. Current look on postural tachycardia syndrome
The take-home point is that “hyperadrenergic POTS” should be a diagnosis of inclusion, meaning the tilt test and catecholamine measurements confirm it, rather than a label applied loosely to anyone whose heart races on standing and who seems “too wired.” If symptoms are episodic and severe, or if they started abruptly later in life without a clear trigger, screening for catecholamine-secreting tumors and structural cardiac issues should happen before the POTS label sticks. Getting the diagnosis right is especially consequential here because a missed pheochromocytoma can be life-threatening, while POTS itself, though deeply disabling, is not typically dangerous in the same way.
Living With Hyperadrenergic POTS Long-Term
Long-term outcome data for POTS as a whole shows that the condition is chronic for most people. In a large survey, the mean symptom duration was nearly ten years, and 99 percent of patients reported ongoing symptoms.6PubMed Central. Long-Term POTS Outcomes Survey: Diagnosis, Therapy, and Clinical Outcomes Quality of life measures showed the greatest limitations in energy and general health. Female patients reported worse symptom severity overall. These findings don’t break down by subtype, so it is hard to say whether hyperadrenergic POTS has a different trajectory than neuropathic POTS. Clinically, though, the hyperadrenergic form is often the more treatment-responsive subtype, because medications that directly lower sympathetic output can make a measurable difference in catecholamine levels and symptom burden.
Day-to-day management tends to be a process of stacking small interventions: consistent fluid and salt intake, a structured exercise program, compression garments, scheduled rest, and medication adjustments based on symptom patterns. Many patients learn to identify their triggers, whether that is heat, prolonged standing, large meals, or hormonal fluctuations, and structure their routines around them. The condition demands patience and self-advocacy, particularly given the average delay to diagnosis and the frequency of misdiagnosis. Finding a clinician with autonomic expertise, even if it means a virtual consultation with a specialist center, can make the difference between years of confusion and a coherent treatment plan.